How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?
To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.
Characterization of the micronized drug is important to understand its bulk properties and design downstream processes and manufacturing approaches.
Optimal dose development and manufacturing.
A holistic approach to the development and manufacture spray dried dispersions.
Strategies on incorporating patient opinion into early drug design and boost patient adherence.
Avoid some of the limitations of conventional tablet dose forms & more.
Increase chances of success in drug development by focusing on API optimization from the start.
Handle small amounts of API or formulation at the early stages of development.
Limit individual variability of type I & II systems with adequate choice of composition.
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
An explanation of OptiGel Bio™ technology as a delivery tool for macromolecule NCE candidates.
RP Scherer Technology can improve timelines and commercialization potential.